Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
BIO Transcript
Bio-Rad Laboratories, Inc. (BIO) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Neutral5-19
Bio-Rad Laboratories, Inc. (BIO) Q1 2026 Earnings Call Transcript
Unknown5-1
The earnings call reveals mixed factors: modest revenue growth, strong ddPCR performance, and strategic M&A focus are positives, yet geopolitical challenges and soft consumable sales are concerns. Unclear management responses and mid-single-digit organic growth decline further neutralize sentiment. The market may react cautiously, but with no drastic movements expected.
Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript
Unknown2-12
The earnings call presents a mixed picture: modest revenue growth in diagnostics and improved free cash flow contrast with declining margins and net income. The Q&A reveals cautious management guidance and uncertainties in process chromatography. Despite strong growth in ddPCR and cash reserves, the lack of buyback and management's vague responses temper optimism. Overall, the sentiment is neutral, with no strong catalysts for significant stock movement.
Bio-Rad Laboratories, Inc. (BIO) Q3 2025 Earnings Call Transcript
Unknown10-29
The earnings call presents a mixed picture: while there is optimism in product development and partnerships, financial metrics show declining cash flow and net loss. The guidance is cautious, with some positive outlooks, but uncertainties in key markets like China and the Americas persist. The Q&A reveals optimism in certain areas, but management's vague responses on growth and market challenges add uncertainty, balancing positive developments. Overall, the sentiment remains neutral as positive and negative factors offset each other.
BIO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
